TBPMF - Tetra Bio-Pharma to acquire exclusive distribution rights for Dronabinol Soft Gel

Tetra Bio-Pharma ([[TBPMF]] -0.7%) entered into a definitive agreement with U.S. strategic partner to acquire the Canadian exclusive rights for Dronabinol Soft Gel capsules for two undisclosed milestones.Tetra will be submitting a new drug submission application in FQ4 to obtain its first Drug Identification Number for a THC-based prescription drug.50% is at the transaction approval and the other 50% once the DIN is granted by Health Canada; Dronabinol DIN launch is expected in 1H21.With the acquisition, Tetra will have an immediate and direct commercial presence in Canada thereby enabling Tetra to establish a revenue stream based on a synthetic cannabinoid drug for major markets in Chemotherapy Induced Nausea and Vomiting.With dronabinol, the company will be able to introduce CAUMZ to the marketplace; addressable market is estimated to be $80M CDN by 2022.

For further details see:

Tetra Bio-Pharma to acquire exclusive distribution rights for Dronabinol Soft Gel